Efficacy of Leuprolide Combined with Abiraterone and Bicalutamide in the Treatment of High-risk Prostate Cancer and Impact on Patients'Quality of Life
Objective To investigate the effect of leuprolide and bicalutamide combined with abiraterone in the treat-ment of high-risk prostate cancer.Methods 65 high-risk prostate cancer patients were selected as study subjects,and according to the different treatment methods,31 cases treated with leuprolide combined with bicalutamide were treated as the control group,and 34 cases treated with abiraterone on the basis of the control group were treated as the experimental group.The clinical effica-cy,international prostate symptoms scales(IPSS),prostate volume,maximum urine flow rate,serological indicators[prostate-spe-cific antigen(PSA),vascular endothelial growth factor(VEGF)]and quality of life[the functional assessment of cancer therapy-prostate(FACT-P)quality of survival scale]were compared between the 2 groups before and after three cycles of treatment.Re-sults The objective effective rate and disease control rate of the experimental group were 29.41％and 47.06％,respectively,which were higher than those of the control group of 6.45％and 22.58％(P＜0.05).After 3 cycles of treatment,ISPP score,prostate volume,PSA,and VEGF showed a decreasing trend in both groups and were lower in the experimental group than in the control group;maximal urinary flow rate showed an increasing trend and was higher in the experimental group than in the control group(P＜0.05).After 3 cycles of treatment,the FACT-P score of the 2 groups showed an increasing trend,and the experimental group was higher than in the control group(P＜0.05).Conclusion Leuprelin and bicalutamide combined with abiraterone is ef-fective in the treatment of high-risk prostate cancer,which can inhibit tumor progression,optimize urination function,relieve clini-cal symptoms and improve quality of life.
LeprerelinBicalutamideAbirateroneHigh riskProstate cancerQuality of life
万方数据
维普
